Enveric Biosciences, Inc. Common Stock (ENVB) is a publicly traded Healthcare sector company. As of May 21, 2026, ENVB trades at $2.20 with a market cap of $4.27M and a P/E ratio of -0.16. ENVB moved +6.16% today. Year to date, ENVB is -45.41%; over the trailing twelve months it is -86.42%. Its 52-week range spans $1.71 to $99.90. Rallies surfaces ENVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Enveric Biosciences Advances EB-003 Toward IND, Reports $1.6M Q1 Loss: Enveric Biosciences reported a Q1 net loss of $1.6 million ($1.08/share) on cash-on-hand of $4.9 million, raising $2.8 million through offerings and securing $5 million at a private placement close with up to $13.9 million potential proceeds. The company advanced its lead candidate EB-003 toward IND-enabling studies after preclinical assays demonstrated dual Gq and β-arrestin signaling at 5-HT2A receptors and a rapid reduction in conditioned fear response.
| Metric | Value |
|---|---|
| Price | $2.20 |
| Market Cap | $4.27M |
| P/E Ratio | -0.16 |
| EPS | $-13.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $99.90 |
| 52-Week Low | $1.71 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $-411 |
| Net Income | $-8.22M |
| Gross Margin | 0.00% |
ENVB analyst coverage data. Average price target: $0.00.